Product news

Share this article:
FDA has approved Takeda's Uloric (febuxostat), indicated for the chronic management of hyperuricemia in patients with gout. The once-daily product represents the first new treatment option in more than 40 years, according to a company release.
 
Device manufacturer C.R. Bard announced an FDA pre-market approval for its LifeStent FlexStar and FlexStar XL Vascular Stent Systems. The devices are approved for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries, and are marketed by Bard's peripheral vascular division, in Tempe, AZ. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions